Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …

Patients with chronic lymphocytic leukemia (CLL) have an impaired antibody response to
coronavirus disease 2019 (COVID-19) vaccination. Here, we evaluated the antibody …

COI notes: Dr. Dhakal has served on the advisory board of Takeda, Amgen, and Jansen. He
has received honorarium from Celgene. Mehdi Hamadani reports Research …

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …

Background Patients with immunocompromised disorders have mainly been excluded from
clinical trials of vaccination against COVID-19. Thus, the aim of this prospective clinical trial …

Background Efficacy and safety data of COVID-19 vaccines among cancer populations have
been limited; however, preliminary data from recent studies have emerged regarding their …

T-cell immunity is central for control of COVID-19, particularly in patients incapable of
mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of …

Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an
important preventive option against coronavirus disease 2019 (COVID-19), especially in …